Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Theronomic Ova-All Care
- Development stage
- Unknown
- Lead developer
- Theronomic
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Theronomic Ova-All Care is a multi-ingredient dietary supplement, marketed as a "tribiotic," designed to support ovarian health and manage symptoms of Polycystic Ovarian Syndrome (PCOS). Developed by the Australian company Theronomic, the formulation combines insulin-sensitizing agents, specifically myo-inositol and D-chiro-inositol, with a "tribiotic" complex consisting of prebiotics, probiotics, and postbiotics. It also includes supportive nutrients such as alpha-lipoic acid, coenzyme Q10, vitamin D3, and folate. The product aims to address the hormonal imbalances, metabolic disturbances, and gut dysbiosis often associated with PCOS by improving insulin sensitivity and modulating the gut-ovarian axis. It is administered orally in capsule form and is currently being evaluated in clinical trials for its effect on biomarkers of ovarian health.
- Brand names
- Ova-All Care
- Other names
- Theronomic Ova-All Care
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on Theronomic Ova-All Care.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theronomic Ova-All Care.